| Not Yet Recruiting | Disease Characteristics of R-CAD NCT07239921 | Peking Union Medical College Hospital | — |
| Completed | AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease NCT05471245 | Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS | N/A |
| Completed | STAR and Deferred Stenting Study NCT05089864 | Saint Luke's Health System | N/A |
| Recruiting | COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting w NCT06075602 | Luzerner Kantonsspital | — |
| Recruiting | SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Tr NCT04988685 | Luzerner Kantonsspital | — |
| Unknown | Physiology and Residual Ischemia After Percutaneous Coronary Intervention NCT04494750 | Laval University | — |
| Active Not Recruiting | SELUTION SLR™ 014 In-stent Restenosis NCT04280029 | M.A. Med Alliance S.A. | N/A |
| Completed | Treatment of In-Stent Restenosis 2 Study NCT03667313 | University Hospital Ostrava | Phase 3 |
| Completed | Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting St NCT04475380 | Foundation of Cardiovascular Research and Education Enschede | — |
| Completed | Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon NCT03242096 | InnoRa GmbH | N/A |
| Unknown | Restenosis in Coronary Stents And Cutaneous HEaLing NCT04915391 | Fundación para la Investigación Biosanitaria del Principado de Asturias | — |
| Withdrawn | DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold NCT03074305 | Samsung Medical Center | N/A |
| Unknown | Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents NCT02508714 | Thorax Centrum Twente | N/A |
| Completed | Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent R NCT02944890 | ZhuHai Cardionovum Medical Device Co., Ltd. | N/A |
| Unknown | Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis NCT02300454 | Mitsui Memorial Hospital | Phase 4 |
| Suspended | Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR NCT02474485 | SIS Medical AG | N/A |
| Completed | Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES NCT02367495 | Deutsches Herzzentrum Muenchen | N/A |
| Completed | EGO-COMBO Clinical End-point Extension Study Beyond 36 Months NCT02263313 | The University of Hong Kong | — |
| Completed | Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis ( NCT02151812 | Hemoteq AG | N/A |
| Completed | To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patien NCT01977534 | Abbott Medical Devices | — |
| Unknown | The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions NCT01915420 | Medical Care Center Prof. Mathey, Prof. Schofer, Ltd. | — |
| Completed | XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study NCT01894152 | Abbott Medical Devices | — |
| Terminated | Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis NCT01967199 | Seung-Jung Park | Phase 4 |
| Completed | ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Sc NCT01759290 | Abbott Medical Devices | — |
| Completed | Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-R NCT01674803 | Foundation of Cardiovascular Research and Education Enschede | N/A |
| Completed | Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis. NCT01651390 | Biotronik AG | N/A |
| Completed | ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold NCT01583608 | Medical Care Center Prof. Mathey, Prof. Schofer, Ltd. | — |
| Completed | Safety Study of a Bioresorbable Coronary Stent NCT01262703 | REVA Medical, Inc. | N/A |
| Completed | XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study NCT01249027 | Abbott Medical Devices | — |
| Unknown | DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity NCT02175706 | Thorax Centrum Twente | N/A |
| Completed | DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population NCT01331707 | Foundation of Cardiovascular Research and Education Enschede | Phase 4 |
| Completed | EXCEL Clinical Trial (Universal Registry) NCT01205789 | Abbott Medical Devices | — |
| Completed | OCT Evaluation of Healing of COMBO Stent NCT01274234 | Prof. Stephen Lee | Phase 1 / Phase 2 |
| Completed | EXCEL Clinical Trial NCT01205776 | Abbott Medical Devices | N/A |
| Completed | XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) NCT01178268 | Abbott Medical Devices | Phase 4 |
| Completed | A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Po NCT01115933 | Abbott Medical Devices | N/A |
| Completed | XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan NCT01086228 | Abbott Medical Devices | — |
| Completed | ABSORB EXTEND Clinical Investigation NCT01023789 | Abbott Medical Devices | N/A |
| Completed | XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort NCT01106534 | Abbott Medical Devices | Phase 4 |
| Completed | SPIRIT PRIME Clinical Trial NCT00916370 | Abbott Medical Devices | Phase 3 |
| Completed | ABSORB Clinical Investigation, Cohort B NCT00856856 | Abbott Medical Devices | N/A |
| Completed | Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenos NCT00882219 | Abbott Medical Devices | Phase 3 |
| Completed | The Effects of Bindarit in Preventing Stent Restenosis NCT01269242 | Aziende Chimiche Riunite Angelini Francesco S.p.A | Phase 2 |
| Unknown | PIoglitazone for PrEvention of Restenosis in Diabetic Patients NCT00376870 | University of Rome Tor Vergata | Phase 3 |
| Completed | XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up NCT01120379 | Abbott Medical Devices | — |
| Completed | XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study NCT00631228 | Abbott Medical Devices | — |
| Completed | The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente NCT01066650 | Foundation of Cardiovascular Research and Education Enschede | Phase 4 |
| Completed | Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal NCT00589810 | The Cleveland Clinic | — |
| Completed | SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of NCT01171820 | Abbott Medical Devices | Phase 4 |
| Completed | SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe NCT00402272 | Abbott Medical Devices | Phase 4 |
| Unknown | Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial NCT00500279 | Seoul National University Hospital | Phase 4 |
| Unknown | Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation NCT00426049 | German Heart Institute | Phase 3 |
| Completed | SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents NCT00714545 | Scripps Health | Phase 4 |
| Completed | ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investiga NCT00300131 | Abbott Medical Devices | — |
| Completed | Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de N NCT00752362 | Sahajanand Medical Technologies Limited | Phase 4 |
| Completed | Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents NCT00552669 | Centro de estudios en Cardiologia Intervencionista | Phase 4 |
| Terminated | Serp-1 for the Treatment of Acute Coronary Syndrome NCT00243308 | Viron Therapeutics Inc | Phase 2 |
| Completed | Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries NCT00248066 | Sarepta Therapeutics, Inc. | Phase 2 |
| Completed | Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis NCT00124943 | Celgene Corporation | Phase 1 / Phase 2 |
| Completed | SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System NCT00180310 | Abbott Medical Devices | Phase 3 |
| Completed | Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries NCT00140101 | Abbott Medical Devices | Phase 2 |
| Completed | The SCRIPPS DES REAL WORLD Registry NCT00714623 | Paul S Teirstein, MD | — |
| Completed | PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions NCT00180466 | Abbott Medical Devices | — |
| Completed | Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries NCT00148356 | Abbott Medical Devices | Phase 2 / Phase 3 |
| Completed | Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II) NCT00409981 | University Hospital, Saarland | Phase 1 / Phase 2 |
| Completed | Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by An NCT00162357 | Lantheus Medical Imaging | Phase 4 |
| Completed | Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I) NCT00106587 | University Hospital, Saarland | Phase 1 / Phase 2 |
| Completed | Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment NCT00287573 | Boston Scientific Corporation | Phase 2 / Phase 3 |
| Completed | Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI NCT00412126 | Hamilton Health Sciences Corporation | N/A |
| Completed | Oral Sirolimus for In-Stent Restenosis NCT00859183 | Deutsches Herzzentrum Muenchen | Phase 4 |
| Completed | A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Ag NCT00055510 | Chugai Pharma USA | Phase 2 / Phase 3 |